Biblio
2023
van de Donk NWCJ, Minnema MC, van der Holt B, Schjesvold F, Wu KLung, Broijl A, Roeloffzen WWH, Gadisseur A, Pietrantuono G, Pour L, et al. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. Lancet Oncol. 2023.
2022
Yong K, Wilson W, de Tute RM, Camilleri M, Ramasamy K, Streetly M, Sive J, Bygrave CA, Benjamin R, Chapman M, et al. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase. Lancet Haematol. 2022.